van der Schoot CE - Search Results

1

PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. Stutterheim J, et al. Among authors: van noesel mm, van der schoot ce. J Clin Oncol. 2008 Nov 20;26(33):5443-9. doi: 10.1200/JCO.2007.13.6531. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838715

2

Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation.

Dercksen MW, Rodenhuis S, Dirkson MK, Schaasberg WP, Baars JW, van der Wall E, Slaper-Cortenbach IC, Pinedo HM, Von dem Borne AE, van der Schoot CE, et al. Dercksen MW, et al. Among authors: van der wall e, van der schoot ce. J Clin Oncol. 1995 Aug;13(8):1922-32. doi: 10.1200/JCO.1995.13.8.1922. J Clin Oncol. 1995. PMID: 7543561

3

Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.

Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AE, van der Schoot CE. Steenbergen EJ, et al. Among authors: van den berg h, van der schoot ce, van leeuwen ef. Leukemia. 1995 Oct;9(10):1726-34. Leukemia. 1995. PMID: 7564517

4

Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease.

Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, von dem Borne AE, van der Schoot CE. Steenbergen EJ, et al. Among authors: van den berg h, van der schoot ce, van leeuwen ef. Blood. 1995 Jul 15;86(2):692-702. Blood. 1995. PMID: 7606000 Free article.

5

IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.

Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, von dem Borne AE, van der Schoot CE. Steenbergen EJ, et al. Among authors: van den berg h, van der schoot ce, van leeuwen ef. Leukemia. 1995 Jan;9(1):216-22. Leukemia. 1995. PMID: 7845021

6

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.

Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ. Pongers-Willemse MJ, et al. Among authors: van dongen jj, van der schoot ce. Leukemia. 1998 Dec;12(12):2006-14. doi: 10.1038/sj.leu.2401246. Leukemia. 1998. PMID: 9844931

7

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia.

Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, van Wering ER, van Dongen JJ, van der Schoot CE. Verhagen OJ, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2000 Aug;14(8):1426-35. doi: 10.1038/sj.leu.2401801. Leukemia. 2000. PMID: 10942239

8

Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.

de Haas V, Oosten L, Dee R, Verhagen OJ, Kroes W, van den Berg H, van der Schoot CE. de Haas V, et al. Among authors: van den berg h, van der schoot ce. Br J Haematol. 2000 Dec;111(4):1080-6. doi: 10.1046/j.1365-2141.2000.02434.x. Br J Haematol. 2000. PMID: 11167743 Free article.

9

Risk assessment in ALL in children: a focus on PCR-based techniques for MRD detection.

de Haas V, van der Schoot CE, van den Berg H. de Haas V, et al. Among authors: van den berg h, van der schoot ce. Ann Oncol. 2001 May;12(5):587-92. doi: 10.1023/a:1011165510924. Ann Oncol. 2001. PMID: 11432614 Free article. Review. No abstract available.

10

The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.

de Haas V, Breunis WB, Dee R, Verhagen OJ, Kroes W, van Wering ER, van Dongen JJ, van den Berg H, van der Schoot CE. de Haas V, et al. Among authors: van dongen jj, van den berg h, van der schoot ce, van wering er. Br J Haematol. 2002 Jan;116(1):87-93. doi: 10.1046/j.1365-2141.2002.03228.x. Br J Haematol. 2002. PMID: 11841400 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

354 results

Search Page